Oklo Shares Slide as Earnings Miss and Insider Selling Collide with SMR Sector Turmoil

Earnings Miss and Cash Burn Concerns

Oklo Inc. (OKLO) is facing a difficult trading session on Tuesday, with shares gapping down to $53.62 on volume of 1.7 million shares. The primary driver of the weakness remains the company's Q4 2025 financial results, which were released late last week. Oklo reported a normalized earnings per share (EPS) loss of $0.27, significantly wider than the consensus analyst estimate of a $0.17 loss.

As a pre-revenue company in the advanced nuclear space, investors are hypersensitive to cash burn and operational milestones. While the company reported $0.00 in revenue—consistent with its development-stage status—the $0.10 per share miss on the bottom line suggests that administrative and engineering costs are scaling faster than anticipated. The company ended the period with approximately $410 million in cash, but the rising loss from operations, which stood at $36.3 million in the most recent quarter, is beginning to weigh on the valuation of the $9.1 billion firm.

Insider Selling Rattles Investor Confidence

Compounding the earnings disappointment is a wave of insider selling that has come to light in recent SEC filings. CEO Jacob DeWitte recently sold 72,960 shares at an average price of $60.00, representing a nearly 9% reduction in his direct holdings. This follows a larger divestment in January where DeWitte sold over 231,000 shares at prices near $99.

In total, insiders have offloaded approximately 2.07 million shares valued at over $170 million in the past 90 days. For a speculative growth stock like Oklo, which has plummeted from a 2025 high of $194, such heavy selling by top executives often signals to the market that the leadership may see the current valuation as full, despite the stock being down more than 70% from its peak.

Sector Contagion: The NuScale Lawsuit

Oklo is also caught in a broader downdraft affecting the Small Modular Reactor (SMR) sector. Earlier today, a securities fraud class action lawsuit was filed against NuScale Power (SMR), alleging that executives misrepresented the commercial viability of its nuclear modules. This legal development has triggered a "guilt by association" sell-off across the industry, as investors reassess the regulatory and execution risks inherent in the "Nuclear Renaissance."

While Oklo recently achieved a milestone by securing an NRC materials license for its subsidiary, Atomic Alchemy, the market is currently prioritizing risk-off sentiment. The NuScale news has overshadowed Oklo's recent strategic pivot into the medical isotope market, which Bank of America analysts previously described as a potential $10 trillion long-term opportunity for the sector.

Technical Outlook and Analyst Sentiment

Technically, OKLO is in a precarious position. The stock has broken below its 50-day Exponential Moving Average and is currently testing intraday support at the $53.30 level. Analysts have been quick to adjust their expectations; B. Riley recently slashed its price target from $129 to $92, while Barclays lowered its target to $82. Although the consensus remains a "Moderate Buy" with an average target of $86.63, the immediate momentum is firmly with the bears as the stock underperforms the S&P 500 by more than 4% today.